18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

Sponsor
Peking University First Hospital
Study ID
NCT07557225
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • 18F-T2 PET/CT — DIAGNOSTIC_TEST
    18F-T2 is injected intravenously with a dose of 0.05-0.10 mCi/kg. The CT and PET imaging session will begin approximately 60 minutes after 18F-T2 administration.

Study Details

The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.

Key Dates

First listed
Apr 29, 2026
Start date
Apr 27, 2026
Status verified
May 2026
Primary completion
Sep 30, 2028
Completion
Mar 31, 2029

Study Design

Enrollment
200 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: 18F-T2 PET/CT
    Participants with tumors likely to express high levels of CAIX will receive an intravenous injection of 18F-T2 followed by PET/CT imaging. The participants will also receive a whole-body 18F-FDG PET/CT scan within a one-week period.

Primary Outcome Measure

The Diagnostic Sensitivity and Specificity of 18F-T2 PET/CT in the Evaluation of CAIX Positive Solid Tumors [ Time Frame: From study completion to 1 month after completion ]

Central Contacts

Find similar trials

Nationwide
Breast cancer trialsCervical cancer trialsColorectal cancer trialsEndometrial cancer trialsHead and neck cancer trialsLung cancer trialsOvarian cancer trialsPancreatic cancer trialsOncology trialsBreast oncology trialsWomen's health trialsGynecologic oncology trialsGI oncology trialsENT trialsLung oncology trialsLung disease trials

Related Studies